Estrella Biopharma is pioneering advancements in T-cell immunotherapy, particularly through its proprietary CD19-Redirected ARTEMIS T Cell technology. This innovative approach aims to enhance the efficacy of T-cell therapies while minimizing the severe side effects commonly associated with traditional CAR T-cell therapies, such as Cytokine Release Syndrome (CRS) and neurotoxicity. The ARTEMIS T Cells utilize a unique structure that allows them to form a multimeric signaling complex with the T-cell receptor, leveraging the natural activation pathways of T cells. In clinical studies, this technology has demonstrated promising results, with a significant percentage of patients achieving favorable responses without severe adverse effects.

In addition to its focus on blood cancers, Estrella Biopharma is also addressing the challenges of treating solid tumors, which represent a significant portion of cancer cases. The company employs a "mark-and-kill" strategy, utilizing an oncolytic virus to induce the expression of the CD19 protein on solid tumor cells. This enables the CD19-Redirected ARTEMIS T Cells to target and eliminate these marked tumors, thereby expanding the potential applications of T-cell therapies to a broader range of cancer types. Through these innovative technologies, Estrella Biopharma is committed to advancing novel T-cell therapies for various unmet medical needs, including both hematologic malignancies and autoimmune diseases.

United States

Developing transformative cancer medicines with CD19-Redirected ARTEMIS T Cells to improve patients’ lives

Estrella Biopharma

Company Details